Cargando…

Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer

BACKGROUND: Bladder cancer (BLCA) is a malignant tumor with a dismay outcome. Increasing evidence has confirmed that chromatin regulators (CRs) are involved in cancer progression. Therefore, we aimed to explore the function and prognostic value of CRs in BLCA patients. METHODS: Chromatin regulators...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ke, Liu, Xiaoqiang, Deng, Wen, Wang, Gongxian, Fu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819906/
https://www.ncbi.nlm.nih.gov/pubmed/35125116
http://dx.doi.org/10.1186/s41065-021-00212-x
_version_ 1784646142363959296
author Zhu, Ke
Liu, Xiaoqiang
Deng, Wen
Wang, Gongxian
Fu, Bin
author_facet Zhu, Ke
Liu, Xiaoqiang
Deng, Wen
Wang, Gongxian
Fu, Bin
author_sort Zhu, Ke
collection PubMed
description BACKGROUND: Bladder cancer (BLCA) is a malignant tumor with a dismay outcome. Increasing evidence has confirmed that chromatin regulators (CRs) are involved in cancer progression. Therefore, we aimed to explore the function and prognostic value of CRs in BLCA patients. METHODS: Chromatin regulators (CRs) were acquired from the previous top research. The mRNA expression and clinical information were downloaded from TCGA and GEO datasets. Cox regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis were performed to select the prognostic gene and construct the risk model for predicting outcome in BLCA. The Kaplan-Meier analysis was used to assess the prognosis between high- and low-risk groups. We also investigated the drug sensitivity difference between high- and low-risk groups. CMAP dataset was performed to screen the small molecule drugs for treatment. RESULTS: We successfully constructed and validated an 11 CRs-based model for predicting the prognosis of patients with BLCA. Moreover, we also found 11 CRs-based model was an independent prognostic factor. Functional analysis suggested that CRs were mainly enriched in cancer-related signaling pathways. The CR-based model was also correlated with immune cells infiltration and immune checkpoint. Patients in the high-risk group were more sensitive to several drugs, such as mitomycin C, gemcitabine, cisplatin. Eight small molecule drugs could be beneficial to treatment for BLCA patients. CONCLUSION: In conclusion, our study provided novel insights into the function of CRs in BLCA. We identified a reliable prognostic biomarker for the survival of patients with BLCA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41065-021-00212-x.
format Online
Article
Text
id pubmed-8819906
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88199062022-02-08 Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer Zhu, Ke Liu, Xiaoqiang Deng, Wen Wang, Gongxian Fu, Bin Hereditas Research BACKGROUND: Bladder cancer (BLCA) is a malignant tumor with a dismay outcome. Increasing evidence has confirmed that chromatin regulators (CRs) are involved in cancer progression. Therefore, we aimed to explore the function and prognostic value of CRs in BLCA patients. METHODS: Chromatin regulators (CRs) were acquired from the previous top research. The mRNA expression and clinical information were downloaded from TCGA and GEO datasets. Cox regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis were performed to select the prognostic gene and construct the risk model for predicting outcome in BLCA. The Kaplan-Meier analysis was used to assess the prognosis between high- and low-risk groups. We also investigated the drug sensitivity difference between high- and low-risk groups. CMAP dataset was performed to screen the small molecule drugs for treatment. RESULTS: We successfully constructed and validated an 11 CRs-based model for predicting the prognosis of patients with BLCA. Moreover, we also found 11 CRs-based model was an independent prognostic factor. Functional analysis suggested that CRs were mainly enriched in cancer-related signaling pathways. The CR-based model was also correlated with immune cells infiltration and immune checkpoint. Patients in the high-risk group were more sensitive to several drugs, such as mitomycin C, gemcitabine, cisplatin. Eight small molecule drugs could be beneficial to treatment for BLCA patients. CONCLUSION: In conclusion, our study provided novel insights into the function of CRs in BLCA. We identified a reliable prognostic biomarker for the survival of patients with BLCA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41065-021-00212-x. BioMed Central 2022-02-07 /pmc/articles/PMC8819906/ /pubmed/35125116 http://dx.doi.org/10.1186/s41065-021-00212-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhu, Ke
Liu, Xiaoqiang
Deng, Wen
Wang, Gongxian
Fu, Bin
Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer
title Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer
title_full Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer
title_fullStr Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer
title_full_unstemmed Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer
title_short Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer
title_sort identification of a chromatin regulator signature and potential candidate drugs for bladder cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819906/
https://www.ncbi.nlm.nih.gov/pubmed/35125116
http://dx.doi.org/10.1186/s41065-021-00212-x
work_keys_str_mv AT zhuke identificationofachromatinregulatorsignatureandpotentialcandidatedrugsforbladdercancer
AT liuxiaoqiang identificationofachromatinregulatorsignatureandpotentialcandidatedrugsforbladdercancer
AT dengwen identificationofachromatinregulatorsignatureandpotentialcandidatedrugsforbladdercancer
AT wanggongxian identificationofachromatinregulatorsignatureandpotentialcandidatedrugsforbladdercancer
AT fubin identificationofachromatinregulatorsignatureandpotentialcandidatedrugsforbladdercancer